Menu
Menu
J Clin Aesthet Dermatol. 2023;16(1):14-17. by Karen Konkel, MD; Melissa Reyes, MD, MPH, FAAD; Ida-Lina Diak, PharmD, MS; Kelly Cao, PharmD; and Lynda McCulley, PharmD, BCPS Drs. Konkel, Reyes, Diak,
Objective. We sought to evaluate the safety, tolerability, and patterns of use for the once-daily oral, narrow-spectrum antibiotic sarecycline in patients with moderate-to-severe acne vulgaris during a 40-week Phase III, multicenter, open-label extension study.
